Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -2891.8%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $31M | $118M | $206M | $95M | $485M | $1.1B | $2.1B | $938M | $1.1B | $1.3B | $215M |
| Enterprise Value | $37M | $124M | $194M | $88M | $427M | $953M | $2.0B | $902M | $1.0B | $1.3B | $197M |
| P/E Ratio → | -0.17 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.78 | 2.98 | 3.56 | 0.54 | 4.35 | 9.79 | 17.75 | 9.16 | 13.18 | 35.02 | 11.10 |
| P/B Ratio | — | — | 9.04 | 1.14 | 1.64 | 2.89 | 4.22 | 2.17 | 3.03 | 6.82 | 1.58 |
| P/FCF | — | — | — | — | — | — | 13.52 | — | — | 172.40 | — |
| P/OCF | — | — | — | — | — | — | 12.35 | — | 29.95 | 114.55 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.12 | 3.36 | 0.50 | 3.84 | 8.61 | 17.00 | 8.81 | 11.84 | 34.33 | 10.16 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 12.95 | — | — | 169.02 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.8% | 80.8% | 100.0% | 100.0% | 89.1% | 100.0% | -52.8% | -42.5% | -36.0% | -79.7% | -238.4% |
| Operating Margin | -273.1% | -273.1% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% | -102.7% | -91.4% | -154.1% | -374.2% |
| Net Profit Margin | -310.8% | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% | -80.9% | -149.2% | -369.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2891.8% | -2891.8% | -185.4% | -136.5% | -57.4% | -40.9% | -26.0% | -23.8% | -24.6% | -33.7% | -43.6% |
| ROA | -152.4% | -152.4% | -73.4% | -70.8% | -29.9% | -21.5% | -15.4% | -15.5% | -15.6% | -24.5% | -38.2% |
| ROIC | -5405.6% | -5405.6% | -178.8% | -131.1% | -62.6% | -42.1% | -24.1% | -24.2% | -27.7% | -30.1% | -45.2% |
| ROCE | -295.5% | -295.5% | -119.9% | -96.4% | -38.5% | -26.4% | -19.0% | -19.5% | -20.5% | -29.2% | -42.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.34 | 0.46 | 0.15 | 0.13 | 0.08 | 0.10 | 0.08 | 0.13 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.50 | -0.09 | -0.19 | -0.35 | -0.18 | -0.08 | -0.31 | -0.13 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.58 | — | — | -3.38 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.54 | 11.25 |
| Quick Ratio | 0.84 | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.57 | 11.27 |
| Cash Ratio | 0.49 | 0.49 | 0.92 | 1.70 | 2.49 | 2.94 | 4.47 | 5.19 | 5.10 | 5.42 | 10.72 |
| Asset Turnover | — | 0.66 | 0.57 | 1.07 | 0.20 | 0.15 | 0.13 | 0.16 | 0.14 | 0.13 | 0.12 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 97.02 | 29.04 | 8.42 | 14.67 | 20.98 | 19.33 | 133.95 | 21.82 | 35.76 | 97.82 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 7.4% | — | — | 0.6% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $280M | $202M | $174M | $154M | $145M | $134M | $112M | $97M | $78M | $71M |
Imminent liquidity and solvency
With a price-to-sales ratio of 0.42, Sangamo's valuation appears to be pricing in a high probability of terminal failure, as reported in recent market data, suggesting that investors are heavily discounting the company's proprietary ZFP platform due to the acute and immediate liquidity constraints currently facing the firm.
The current P/S multiple is significantly compressed compared to gene-editing peers, which may indicate that the market views the company's intellectual property as having limited residual value outside of a potential acquisition or liquidation scenario. This valuation level implies that the market has largely abandoned the prospect of independent commercialization, focusing instead on the company's inability to bridge the gap between its current clinical-stage status and a self-sustaining revenue model.
According to recent financial statements, Sangamo's operating margin of -22.2% in 2026Q1 highlights a structural inability to cover fixed R&D costs, as the reported 100% gross margin is merely an accounting artifact of collaboration revenue rather than a reflection of true, scalable product-based earning power.
The persistent negative operating margins suggest that the company's current business model is fundamentally incapable of achieving profitability without a radical shift toward royalty-based income or a successful commercial launch. Investors should monitor the company's ability to reduce its burn rate, as the current cost structure appears misaligned with the lumpy and unpredictable nature of its milestone-driven revenue streams.
As reported in recent quarterly filings, Sangamo's current ratio has deteriorated to 0.70, indicating that the company's current liabilities now exceed its liquid assets, which poses a severe and immediate risk to its ability to meet short-term operational obligations without securing additional, likely dilutive, capital.
The decline in the quick ratio to 0.70 suggests that the company lacks the necessary cushion to absorb even minor operational setbacks or delays in clinical milestones. This liquidity position warrants extreme caution, as the firm's reliance on external financing in a high-rate environment could lead to significant equity dilution for existing shareholders.
The price-to-sales ratio is frequently misapplied to Sangamo, as it obscures the binary nature of milestone-based revenue and fails to account for the company's massive cash burn, making a cash-burn-to-runway analysis a far more accurate metric for assessing the firm's actual survival prospects and financial health.
Using P/S in a pre-revenue or milestone-dependent biotech firm like Sangamo provides a false sense of valuation stability, as it ignores the fact that current revenue does not represent recurring cash flow. Analysts should instead focus on the cash-to-burn ratio, which provides a clearer picture of the company's remaining time to achieve a value-inflection clinical milestone before requiring further capital.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SGMO stock.
Sangamo Therapeutics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Sangamo Therapeutics, Inc.'s return on equity (ROE) is -2891.8%. The historical average is -44.1%.
Based on historical data, Sangamo Therapeutics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sangamo Therapeutics, Inc. has 80.8% gross margin and -273.1% operating margin.